Surterra partners with Intrexon in $100 million licensing cannabinoid deal

Women, minority execs show few gains in U.S. cannabis industry, according to the latest data from the MJBiz Diversity, Inclusion and Equity Report. Get your copy here.


Surterra Wellness, an Atlanta-based cannabis company with operations in Florida and Texas, announced it will partner with Hungary’s Intrexon Corp. in a $100 million licensing deal aimed at biosynthetic cannabinoid production.

Surterra would use Intrexon’s proprietary yeast fermentation platform to boost its cannabinoid production.

Surterra is a privately held company; Intrexon trades on the Nasdaq under the ticker symbol XON.

This is the second deal between the two companies this year: They earlier announced a collaboration on cannabis plant propagation.

More details on the cannabinoid agreement can be found here.

Get access to more in-depth market analysis, premium features on cannabis investing trends and monthly executive webcasts with an Investor Intelligence subscription.